Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABBV-461 + CLBR001 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABBV-461 | ABBV 461|ABBV461 | ABBV-461 comprises an antibody fragment targeting an undisclosed tumor-associated antigen linked to a peptide epitope that is recognized by CRBL001 CAR-T cells, which potentially induces activation of CRBL001 CAR-T cells and tumor cell killing (NCI Drug Dictionary). | ||
| CLBR001 | CLBR-001|CLBR 001|Autologous alpha-PNE CAR T-cells CLBR001 | CLBR001 is a switchable CAR-T therapy that comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets a unique peptide epitope on a tumor antigen-specific switch molecule, which potentially results in activation of CAR-T cells and tumor cell killing in the presence of the switch molecule (Blood (2021) 138 (Supplement 1): 1695, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06878248 | Phase I | ABBV-461 + CLBR001 | A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer | Recruiting | USA | 0 |